1. Nidoviruses, an introduction {#s0005}
===============================

The order *Nidovirales* currently comprises four families -- the *Coronaviridae, Arteriviridae, Roniviridae,* and *Mesoniviridae* - that span across a wide range of hosts, including mammalian, avian, reptile, fish, and invertebrate species (<https://talk.ictvonline.org/taxonomy/>). Within this order, the coronaviruses and arteriviruses have been studied in most detail, due to the societal and economic impact of some family members, unusual features of their pathogenesis, and the complexity of their molecular biology. The latter includes having large to very large polycistronic positive-strand RNA genomes, with sizes ranging from 13 to 16 kb for arteriviruses, via \~ 20 kb for *meso*niviruses, to 26--34 kb for roni- and coronaviruses ([@bib36], [@bib88]). The best-known members of the arterivirus family are porcine reproductive and respiratory syndrome virus (PRRSV) and equine arteritis virus (EAV). The coronaviruses (CoVs) are classified into two subfamilies: the *Torovirinae* and the *Coronavirinae*, the latter being subdivided into the genera *Alpha*-, *Beta*-, *Gamma*-, and *Deltacoronavirus*. Most mammalian CoVs are alpha- or betacoronaviruses and these genera include the four 'established' human coronaviruses (HCoVs 229E, OC43, NL63 and HKU1), the zoonotic coronaviruses causing severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) ([@bib128]), and related viruses from bats ([@bib52], [@bib62]) and camels ([@bib104]). Thus far, gamma- and deltacoronaviruses have been discovered mostly in avian species ([@bib139]).

1.1. Societal and economic impact of nidoviruses {#s0010}
------------------------------------------------

In the past 15 years, nidovirus research has been driven forward in particular by the emergence of two life-threatening CoVs in humans, the betacoronaviruses SARS-CoV and MERS-CoV, which most likely originate from bats and were introduced by zoonotic transfer from intermediate hosts, civet cats and dromedary camels for SARS-CoV and MERS-CoV, respectively ([@bib35], [@bib51], [@bib82]). Of note, the presence of neutralizing antibodies in camels suggests that MERS-CoV or related viruses may have been present in this reservoir for decades ([@bib51]). The short-lived SARS-CoV outbreak in 2002--2003 resulted in 8098 reported cases leading to 774 deaths, while affecting 29 countries (<http://www.who.int/csr/sars/en/>). Between its emergence in 2012 and March 2018, MERS-CoV has caused \> 2100 laboratory-confirmed human infections and at least 750 deaths (<http://www.who.int/emergencies/mers-cov/en/>). The clinical presentation of SARS-CoV and MERS-CoV ranges from asymptomatic or mild symptoms to acute respiratory disease, in the case of SARS originally described as an "atypical pneumonia" accompanied by fever and severe respiratory distress ([@bib53]). The SARS-CoV and MERS-CoV outbreaks greatly augmented the interest in the CoV family, although human CoVs had already been known since the 1960\'s, when HCoV-OC43 and HCoV-229E were identified. These two viruses are known to cause mild respiratory disease and, after rhinoviruses, are a leading cause of common colds (10--15% of the cases; reviewed in [@bib130]). More recently, two additional HCoVs were discovered, HCoV-NL63 and HCoV-HKU1, which again are associated with respiratory disease (reviewed in [@bib98]).

The potential impact of nidoviruses as veterinary pathogens is exemplified by the porcine epidemic diarrhea coronavirus (PEDV) and also by the arterivirus PRRSV, which both continue to cause major economic losses in the swine industry worldwide ([@bib47], [@bib65]). Likewise, ronivirus infections have done significant damage in the Asian shrimp farming industry ([@bib27]). Such outbreaks and the threat of additional emerging (zoonotic) nidoviruses, in combination with the lack of effective antiviral strategies, highlight the importance of advancing our knowledge of the replication of the members of this diverse virus order and their interactions with the host.

1.2. Nidovirus molecular biology {#s0015}
--------------------------------

The conserved genome organization and expression strategy of nidoviruses includes the translation of two large replicase open reading frames (ORFs 1a and 1b) from the genomic RNA. This yields the replicase polyprotein (pp) 1a and, following a −1 ribosomal frameshift, the C-terminally extended pp1ab. The two polyproteins are proteolytically processed by multiple internal proteases to liberate (in the case of arteri- and coronaviruses) at least 13--16 nonstructural proteins (nsps). Among these nsps are subunits containing RNA-dependent RNA-polymerase and helicase functions, key players in the enzyme complex responsible for viral RNA synthesis. Together with recruited host cell proteins, nidovirus nsps form membrane-associated replication and transcription complexes ([@bib37], [@bib40], [@bib94], [@bib125], [@bib126]) that localize to a network of virus-induced structures, typically including double-membrane vesicles, in the perinuclear region of the infected cell (reviewed in [@bib137]; [@bib102]; [@bib124]). A nested set of subgenomic (sg) mRNAs is produced to express the structural and accessory proteins that are encoded downstream of the nidovirus replicase gene ([@bib93], [@bib105], [@bib114], [@bib115]). Despite these common features of viruses in the order *Nidovirales*, the various nidovirus taxa differ strikingly in the type, number, and size of their structural proteins, which also explains the observed variation in virion structure and morphology.

The recent outbreaks of emerging nidoviruses inspired extensive studies of their epidemiology and pathogenesis, and underlined the importance of developing prophylactic and therapeutic options, including vaccines and drugs targeting either viral functions or host factors recruited to support nidovirus replication. In this context, the inhibition of a range of RNA viruses by cyclophilin (Cyp) inhibitors ([@bib49]) prompted several research teams to investigate their impact on nidovirus replication, mainly for coronaviruses and - to a lesser extent -- for arteriviruses. Below we will first describe the key features of members of the Cyp family and then summarize our current knowledge regarding their involvement in nidovirus replication. This includes the anti-nidoviral effect of cyclosporin A (CsA), the best known Cyp inhibitor ([@bib5], [@bib42]), and several of its non-immunosuppressive analogs. Finally, our current knowledge on the involvement of Cyps in the replication of other RNA viral pathogens is summarized, to illustrate the wide variety of mechanisms by which this common host factor can be involved in supporting viral replication.

2. Cyclophilins and cyclophilin inhibitors {#s0020}
==========================================

The peptidyl/prolyl isomerases (PPIases) comprise the immunophilin superfamily, to which the Cyps and the FK506-binding proteins (FKBPs) families belong, and the parvulin protein family ([@bib108]). Cyps and FKBPs are ubiquitous in both eukaryotes and prokaryotes, and both protein families were initially identified on the basis of their ability to bind the immunosuppressive drugs CsA ([@bib42]), and FK506 or rapamycin ([@bib59]), respectively. The parvulins were initially discovered in the cytoplasm of *E. coli* ([@bib100]) and are the smallest proteins known to have PPIase activity. This activity is essential for catalyzing the *cis-trans* isomerization of the peptide bond upstream of proline residues, which is a rate-limiting step in protein folding ([@bib60], [@bib110]). The identification of the first protein with PPIase activity ([@bib25]) coincided with the purification from bovine thymocytes of a cellular protein with high affinity for the immunosuppressant CsA: cyclosporin-binding protein A (CypA) ([@bib42]). Five years later, it was discovered that both proteins were one and the same ([@bib26], [@bib117]). Cyps are involved in a wide range of cellular processes, including protein folding, protein trafficking, and cell signaling ([@bib86]). Despite the fact that all members of the PPIase superfamily share the same enzymatic activity, protein sequences and structures differ enormously between the three families ([@bib2], [@bib19], [@bib43]). The human genome is currently believed to encode 19 cyclophilins, 18 FKBPs, and three parvulins (Pin1, Par14, and Par17) ([@bib39]).

Cyclophilins have been identified in a range of organisms, including mammals, plants, insects, fungi, and bacteria ([@bib2], [@bib129]). Not all Cyps catalyze the *cis-trans* isomerization of proline-preceding peptide bonds; in fact in vitro PPIase activity has been demonstrated for only seven of the human Cyps ([@bib19]). Some Cyps, like CypA, consist of solely a PPIase domain, while in other Cyps this domain is flanked by additional sequences or modular domains, which control their subcellular localization and/or are thought to be specific for cellular functions ([@bib2], [@bib107]). Despite the fact that Cyps have been implicated in a range of cellular processes, the function of many Cyps is unknown. Also, it has proven to be difficult to identify the natural substrates of the PPIase activity (reviewed in [@bib49]). Besides their role in specific cellular functions (reviewed in [@bib86]), CypA, CypB, and CypD have been shown to also function in the replication of certain groups of RNA viruses. Below we will briefly summarize the cellular function of these Cyps.

2.1. Cyclophilin A {#s0025}
------------------

The 18-kDa cytosolic CypA is also referred to as peptidyl-prolyl isomerase A (PPIA) or Cyp18. It is one of the most abundant proteins in the cytoplasm (0.1--0.4% of total protein content) and is expressed in all tissues ([@bib45], [@bib103]). In the cytosol, CypA plays a role in a broad range of cellular functions, like facilitating protein folding, protein trafficking, T-cell activation, and cell signaling (reviewed in [@bib86]; [@bib90]). Although CypA normally is an intracellular protein, inflammatory stimuli like infections, hypoxia, or oxidative stress can elicit CypA secretion via a vesicular transport mechanism that depends on Rho kinase activation (reviewed in [@bib8]). CypA proved to be non-essential for cell growth as depletion of CypA in cells or in PPIA^-/-^ knockout mice did not affect survival and/or growth kinetics ([@bib12], [@bib18], [@bib138]).

2.2. Cyclophilin B {#s0030}
------------------

The 22-kDa CypB essentially consists of a PPIase domain that is equipped with a cleavable N-terminal signal sequence to target the protein to the lumen of the endoplasmic reticulum (ER) ([@bib96], [@bib116]). N-terminally truncated CypB is secreted in response to inflammatory stimuli, although the mechanism by which CypB is cleaved is currently unclear (reviewed in [@bib8]). In addition, binding of CsA to the CsA-binding site in CypB induces the release of CypB from the ER via the secretory pathway. It has been hypothesized that this binding of CsA interferes with a functional interaction of CypB with other ER-associated proteins that normally retains CypB ER-associated ([@bib23], [@bib97]).

2.3. Cyclophilin D {#s0035}
------------------

The mitochondrially targeted CypD regulates the mitochondrial permeability transition pore (MPTP) that controls the Ca^2+^ transport from mitochondrion to the cytosol. Upon sensitization to calcium overload and oxidative stress, CypD binds the MPTP to induce opening of the pore to release Ca^2+^. These processes ultimately lead to necrosis ([@bib21], [@bib101]) or necroptosis, a programmed form of necrosis that depends on CypD ([@bib67]). CsA-mediated CypD inhibition or CypD knockout studies in cell culture have been shown to prevent necrosis and CypD^-/-^ mice were resistant to necrotic ([@bib1], [@bib85]) and necroptotic cell death (reviewed in [@bib67]).

2.4. Cyclosporin A and FK-506 {#s0040}
-----------------------------

In the 1970s and 1980s, the immunosuppressive properties of CsA and FK-506 were discovered and revolutionized the field of organ transplantation by reducing the risk of organ rejection (reviewed in [@bib121]). CsA, isolated from the soil fungus *Tolypcladium inflatum,* is a lipophilic, neutral, cyclic endecapeptide ([@bib5]). FK-506 (or Tacrolimus) was isolated from *Streptomyces tsukubaensis* and is functionally but not structurally related to CsA ([@bib38]). The immunosuppressive properties of CsA and FK-506 depend on complex formation with Cyps and FKBP12, respectively. In turn, these complexes sequester and inhibit calcineurin, a serine/threonine protein phosphatase that is a key player in T cell activation ([@bib69]). The interaction with calcineurin inhibits the phosphatase activity of the latter enzyme, which prevents the nuclear translocation of its substrate nuclear factor of activated T cells (NF-AT) and consequently the expression of immune genes like IL-2 and IL-4 ([@bib69]). In this manner, CsA and FK-506 suppress the activation of cytotoxic and helper T cells ([@bib46], [@bib111], reviewed in [@bib80]). These drugs proved to be suitable immunosuppressive agents due to the absence of the toxicity commonly associated with other fungus-derived immunosuppressive pharmaceuticals. Subsequently, CsA also revolutionized the treatment of autoimmune diseases such as rheumatoid arthritis, Crohn\'s disease, and vernal keratoconjunctivitis, as well as various dermatological diseases (reviewed in [@bib49]).

2.5. Non-immunosuppressive CsA analogs {#s0045}
--------------------------------------

CsA has be shown to inhibit the replication of a variety of DNA and RNA viruses in cell culture (see also chapters 3 and 4), but in the context of antiviral therapy, immunosuppression by compounds like CsA would obviously be undesirable. To address this issue, a variety of CsA analogs that do bind Cyps without inducing immunosuppression have been engineered. These second-generation Cyp inhibitors include Alisporivir (ALV; or Debio-025) ([@bib58], [@bib92]), NIM811 ([@bib15]), and SCY-635 ([@bib50]). These compounds have been modified to abolish their affinity for calcineurin, while increasing their affinity for Cyps. As a result, these non-immunosuppressive CsA analogs are more potent inhibitors of the interactions of Cyps with (viral) proteins, while their administration does no longer lead to inhibition of NF-AT signaling, as calcineurin\'s phosphatase activity is not inhibited. Therefore, these drugs have become critical tools to study Cyp functions, cellular signaling pathways, and/or interactions of Cyps that are relevant for viral replication (as discussed in this review). Also, most of these CsA analogs have been explored as antiviral drugs (reviewed in [@bib31]; [@bib49]).

3. Cyps and Cyp inhibitors in nidovirus replication {#s0050}
===================================================

3.1. Cyclophilin inhibitors can block coronavirus replication {#s0055}
-------------------------------------------------------------

Various laboratories have shown that, in cell culture, the replication of members of different CoV genera can be inhibited by CsA treatment. Low-micromolar levels of CsA inhibit the replication of alphacoronaviruses (HCoV-229E, transmissible gastroenteritis virus (TGEV), feline coronavirus (FCoV), and PEDV) ([@bib133], [@bib57], [@bib95], [@bib118]) and betacoronaviruses (mouse hepatitis virus (MHV), SARS-CoV, and MERS-CoV) ([@bib135], [@bib133], [@bib95]). Collectively, these reports established the broad-spectrum anti-coronavirus activity of CsA in cell culture-based infection models (for a complete overview of nidoviruses known to be inhibited by treatment with CsA and/or its analogs, see [Table 1](#t0005){ref-type="table"}).Table 1Overview of the effect of Cyp inhibitors and of Cyps reported to be involved in nidovirus replication.Table 1**Virus*****(family)*****Cyclophilin inhibitorsDepletion of cyclophilinsInhibitorReadoutEC50 (µM)ReferenceCypsAssayObserved effectReference***Arteriviruses*EAVCsA, Debio-064Virus-driven GFP expression, virus yields0.3--1.0 µM([@bib134])CypAsiRNA, shRNA, knockoutInhibition of virus replication([@bib134], [@bib138])PRRSVCsA, Debio-064Virus-driven GFP expression, virus yields5.1--5.2 µM([@bib134])--[d](#tbl1fnStarStarStarStar){ref-type="table-fn"}------*Alphacoronaviruses*HCoV-OC43CsAVirus-induced cell death2.5 µM[c](#tbl1fnStarStarStar){ref-type="table-fn"}([@bib22])CypDCsA treatmentIncreased cell survival by interfering with virus-induced apoptosis([@bib22])HCoV-NL63CsA, ALV, NIM-811, other CsA analogs, FK-506qPCR, virus yields0.8--6.6 µM([@bib11], [@bib10], [@bib95])CypAshRNAInhibition of virus replication([@bib11])HCoV-229ECsA, ALV, FK-506Virus-driven GFP or luciferase expression, virus yields2.3--12.2 µM([@bib10], [@bib136], [@bib133], [@bib95], [@bib7])CypA?shRNA, knockoutInhibition of virus replication in Huh7.5 cells, no effect in Huh7([@bib138], [@bib7])PEDVCsAVirus yields5 µM[c](#tbl1fnStarStarStar){ref-type="table-fn"}([@bib57])--------FCoVCsA, DTM[a](#tbl1fnStar){ref-type="table-fn"}Virus yields2.7--4.1 µM([@bib95], [@bib119], [@bib118], [@bib120])CypA, CypB, Pin1[b](#tbl1fnStarStar){ref-type="table-fn"}shRNA, knockoutInhibition of virus production([@bib95], [@bib119], [@bib120])*Betacoronaviruses*MHVCsA, ALVVirus-driven GFP expression, virus yields6.3--12 µM([@bib136], [@bib133])--------TGEVCsAVirus yields10 µM([@bib95])--------SARS-CoVCsA, ALV, FK-506Virus-driven GFP expression, virus yields8.3--12 µM([@bib10], [@bib136], [@bib133], [@bib95])CypA, CypBsiRNA, shRNANone([@bib133]; de Wilde et al., unpublished observations)MERS-CoVCsA, ALVVirus-induced cell death, virus yields3.4--7.5 µM([@bib136], [@bib135])CypAKnockoutMinor reduction in virus replication([@bib136], [@bib138])*Gammacoronaviruses*IBV (Beaudette)CsAVirus yields5.5 µM([@bib95])--------[^1][^2][^3][^4]

Coronavirus infection in cell culture can also be inhibited by non-immunosuppressive CsA analogs, with EC~50~ values similar to those of CsA. Treatment with ALV led to a two- to five-log reduction of MERS-CoV, HCoV-229E, and SARS-CoV progeny titers (EC~50~ values ranging from 1.3 to 8 µM) ([@bib136]). In addition, similar low-micromolar concentrations of ALV, NIM-811, and other CsA analogs effectively blocked HCoV-NL63 infection ([@bib11]). Notably, for some CoVs variable antiviral effects were observed in different cell types, including Huh7 cells and various Vero cell subtypes, with e.g. the antiviral effect of ALV against SARS-CoV being less pronounced in Vero-E6 cells than in another Vero cell subclone ([@bib136]). The reasons for these variations in antiviral effects are poorly understood, but may include variations in drug uptake, Cyp expression levels, and/or the overall kinetics of virus replication in a particular cell line.

Unfortunately, ALV treatment did not protect mice from a challenge infection with mouse-adapted SARS-CoV, highlighting that inhibition in cell culture infection models does not necessarily translate into an antiviral effect in vivo ([@bib136]). This failure could be taken as a first sign that Cyp inhibitors may not be useful for the clinical treatment of CoV infections. It is clear, however, that this conclusion first needs to be corroborated in further studies, also including other compounds and other coronavirus (or nidovirus) models. This might more rigorously establish whether currently used Cyp inhibitors are worth pursuing, either directly or as leads for the development of other host-directed antiviral drugs. Furthermore, the development of non-immunosuppressive Cyp inhibitors with increased potency, solubility, or drug plasma levels may enhance the antiviral activity in vivo. In any case, the use of Cyp inhibitors in fundamental research may still help to uncover the putative role of Cyps in the replication of CoVs and other nidoviruses, as will be discussed below. Also, a summary of the (putative) roles of Cyps in nidovirus replication is depicted in [Fig. 1](#f0005){ref-type="fig"}.Fig. 1Schematic overview of the presumed role of cyclophilins, FK-506 binding proteins and parvulins in nidovirus replication, as well as the effect of related inhibitors. Blue arrows indicate processes or interactions that positively affect virus replication. In red, inhibitory effects on infection are indicated that are induced by chemical inhibitors, protein-inhibitor complexes, or protein-protein complexes. See chapter 2 and chapter 3 for more details. *Abbreviations:* gRNA (+), positive-stranded genomic nidovirus RNA; pp1a, polyprotein 1a; pp1ab, polyprotein 1ab; RC, replication complex; Caln, calcineurin; CsA, cyclosporin A; Cyp, cyclophilin; FKBP, FK-506 binding protein; Pin-1, Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1; CypI, cyclophilin inhibitors; MPTP, mitochondrial permeability transition pore; nsp, nonstructural protein; IL-2, interleukin-2; DTM, dipentamethylene thiuram monosulfide; P, phosphate; NF-AT, nuclear factor of activated T-cells.Fig. 1

3.2. The potential role of Cyps in coronavirus infection {#s0060}
--------------------------------------------------------

The inhibitory effect of treatment with CsA or its analogs (see above) suggested a role for one or more Cyps as host factor(s) in CoV replication. In 2004, seven years before the first reports on the inhibition of nidovirus replication by Cyp inhibitors, [@bib76] already suggested CypA to be an interaction partner of the SARS-CoV nucleocapsid (N) protein after using surface plasmon resonance to measure the binding affinity of purified SARS-CoV N protein and CypA. In a follow-up study, co-immunoprecipitation of purified CypA with SARS-CoV N protein confirmed the interaction of the two proteins ([@bib14]). Using a similar co-immunoprecipitation approach, CypA was also shown to bind to cellular CD147, which is present on the plasma membrane. It was postulated that a CD147-CypA-N complex could promote SARS-CoV entry ([@bib14]), although the formation of this tri-partite protein complex was not demonstrated. Moreover, a conceptual difficulty is that, during virus entry, the putative virion-associated CypA-N protein complex would be physically separated from CD147 by the viral envelope, and consequently it is difficult to envisage an interaction between these two proteins. Using a mass-spectrometry-based approach, [@bib87] confirmed the presence of CypA in SARS-CoV virions, although no function was proposed for virion-associated CypA.

A yeast two-hybrid (Y2H) screen identified potential interactions between SARS-CoV nsp1 and several cyclophilins (CypA, CypB, CypH, CypG) and FK506-binding proteins (FKBP1A and FKBP1B) ([@bib95]). Subsequently, the importance of CypA as a host factor in CoV replication was further substantiated using knockdown or knockout of CypA expression, which was achieved using a variety of approaches. In Caco-2 and Huh7.5 cells, shRNA-mediated knockdown of CypA mRNA expression to below 3% of the normal levels was reported to nearly completely block HCoV-NL63 replication ([@bib11]) and reduce HCoV-229E-driven luciferase expression by 10- to 20-fold ([@bib7]). CypA- or CypB-knockout in feline fcwf-4 cells resulted in a near-complete block of FCoV replication. Interestingly, in the parental fcwf-4 cells shRNA-mediated knockdown of CypA and CypB only marginally reduced FCoV replication, suggesting that relatively small amounts of CypA and CypB may suffice to support normal levels of FCoV replication. Transient overexpression of PPIase-defective CypA or CypB mutants in parental fcwf-4 cells (still expressing endogenous CypA and CypB) slightly reduced replication, suggesting that PPIase activity of CypA and CypB is relevant for FCoV replication ([@bib120]).

The importance of CypA was further highlighted in infection experiments using Huh7.5-CypA-knockdown cells transiently expressing CypA variants derived from non-synonymous single-nucleotide polymorphism (SNP)-containing PPIA genes. HCoV-229E replication was reduced in cells expressing different CypA variants displaying reduced stability ([@bib7]). The involvement of CypA as host factor in coronavirus replication was further analyzed using MERS-CoV and HCoV-229E infection in CypA-knockout Huh7 cells generated via CRISPR-Cas9 technology. In these cells, compared to control cells, a 3-fold reduction in MERS-CoV titers was observed ([@bib138]), but, interestingly, HCoV-229E replication was unchanged compared to parental Huh7 cells. For HCoV-229E, these results appear to be at odds with the study summarized above in which CypA depletion led to a 10- to 20-fold reduction of HCoV-229E-driven luciferase expression ([@bib7]). Explanations for these contradictory results may include the use of wild-type versus reporter gene-expressing viruses, different readouts of virus replication, and the use of Huh7 instead of Huh7.5 cells.

For SARS-CoV, the role of CypA and/or other Cyps in infection remains unclear. siRNA-mediated CypA depletion ([@bib133]) nor shRNA-mediated depletion of CypA in Vero cells (6% remaining CypA mRNA levels; de Wilde *et al.*, unpublished observations) did not lead to a reduction in SARS-CoV replication. However, since low levels of CypA may suffice to facilitate normal replication of other coronaviruses (as described above for FCoV), the dependence of SARS-CoV on CypA and other Cyps will require the generation of gene knockouts in a cell line permissive to SARS-CoV infection.

CypD has been reported to play a role in PEDV and HCoV-OC43 infection. CypD is part of the mitochondrial permeabilization transition pore and is involved in the caspase-independent cell death induced by PEDV and HCoV-OC43 ([@bib22], [@bib57]), an event that is inhibited by CsA. Upon HCoV-OC43 infection of differentiated LA-N-5 cells, the pro-apoptotic protein BAX re-localizes to mitochondria, where it may interact with CypD. Like CsA treatment, shRNA-mediated knockdown of CypD protected differentiated LA-N-5 cells from HCoV-OC43-induced programmed cell death, suggesting that CypD is involved in programmed cell death, most likely necroptosis, in HCoV-OC43-infected cells ([@bib22]).

The role in CoV infection of Cyps in general and CypA in particular remains elusive. Although Cyps differ in their cellular localization and function (see chapter 2), it is conceivable that other Cyps can substitute for CypA as a host factor in coronavirus replication. One candidate is the ER-associated CypB that may be in close proximity to the site of coronavirus replication, which is also associated with ER-derived membrane structures. However, it should be noted that CypB is located in the lumen of the ER and CypB may be therefore physically separated from the replication complexes on the cytosolic side of the ER membrane. Nevertheless, a CypA/CypB double-knockout cell line, which would prevent one Cyp from substituting for the other, may shed more light on the importance of both these Cyps in CoV replication.

3.3. NF-AT signaling and FKBPs in coronavirus infection {#s0065}
-------------------------------------------------------

[@bib95] showed that SARS-CoV nsp1 binds to Cyps and FKBPs and also influenced NF-AT-regulated gene activation ([Fig. 1](#f0005){ref-type="fig"}). This activation was blocked by CsA treatment ([@bib95]). The authors showed that, in cell culture, SARS-CoV infection in itself is a poor activator of NF-AT signaling, but in the presence of the NF-AT activators phorbol 12-myristate 13-acetate (PMA) and ionomycin SARS-CoV infection further upregulated NF-AT-dependent gene expression compared to cells treated with PMA and ionomycin only. The importance of the NF-AT signaling pathway in coronavirus replication was further investigated using the drug FK-506. Indeed, the replication of SARS-CoV, HCoV-229E, and HCoV-NL63 (EC~50~ of 6.9 µM, 5.4 µM, and 5.1 µM, respectively) was found to be inhibited by FK-506, with a \> 2 log reduction of virus yields at doses above 20 µM ([@bib10]). However, in contrast to the broad-spectrum inhibitory effect of CsA, the replication of some other coronaviruses (TGEV, IBV, and FCoV) was not affected by FK-506 treatment in cell culture ([@bib118], [@bib7]).

3.4. Parvulins are involved in FCoV replication {#s0070}
-----------------------------------------------

The work of [@bib119] implicated a member of the third group of proteins with PPIase activity, parvulins, in CoV infection ([Fig. 1](#f0005){ref-type="fig"}). While FKBP inhibitors did not block FCoV replication in feline fcwf-4 cells, chemical inhibition of Pin1 by dipentamethylene thiuram monosulfide (DTM) reduced it approximately 10-fold. In Pin1-knockout cells, FCoV replication was only marginally affected. Pin1 has been shown to be an important mediator of cell cycle progression ([@bib64]), and has also been implicated as a proviral factor in HCV and HIV-1 infection ([@bib63], [@bib132]). Pin1 depletion led to a 5-fold reduction in HCV replication, which could be compensated by transient expression of wild-type Pin1, but not by expression of PPIase-defective mutant Pin1 ([@bib63]). The involvement of Pin1 in HIV-1 infection is distinct from its role in HCV replication: HIV-1 infection induces Pin1 phosphorylation that in turn reduced expression and virion association of APOBEC3G, a known HIV-1 restriction factor ([@bib132]). At the moment, the role of Pin1 has been investigated for FCoV only, and whether this protein has a general role in CoV infection remains to be investigated further.

3.5. CypA is involved in arterivirus replication {#s0075}
------------------------------------------------

Research on the role of Cyps and Cyp inhibitors in nidovirus infection was extended to the arterivirus family. In line with the inhibitory effect of CsA treatment on CoV replication in cell culture, the replication of the arteriviruses EAV and PRRSV was found to be inhibited in the presence of low-micromolar concentrations of CsA and Debio-064, another non-immunosuppressive CsA analog. Interestingly, with EC~50~ values below 1 µM, replication of EAV was the most sensitive among all nidoviruses tested so far ([@bib134]), suggesting that EAV depends most strongly on Cyps for its replication. Both drugs prevented viral protein expression in arterivirus-infected cells and reduced virus yields by 4 logs ([@bib134]). Likewise, both compounds blocked in vitro RNA synthesis in assays using semi-purified replication structures from EAV-infected cells, pointing towards direct inhibition of viral RNA synthesis. In CsA-resistant EAV mutants, selected by serial passaging in the presence of the compound, mutations primarily mapped to nsp5, a multispanning membrane-associated subunit of the viral replicase. In addition, in vitro RNA synthesis activity of replication complexes prepared from cells infected with CsA-resistant EAV is indeed insensitive to CsA treatment (de Wilde et al., manuscript in preparation). The role of nsp5 in arterivirus replication is poorly understood, but the protein has been suggested to play a role in fine-tuning the conversion of intracellular membranes into viral replication organelles ([@bib124]).

Of note, we previously postulated CypA to be associated with EAV replication organelles as the protein cosediments with membrane-associated EAV replication complexes in density gradients and pre-treatment of these samples with CsA prevents this cosedimentation. The presence of CypA, but not its PPIase activity (de Wilde et al., manuscript in preparation), was indeed shown to be pivotal for EAV replication ([@bib134]) as knockout of CypA expression resulted in a 3-log reduction of EAV progeny yields. Replication was affected much less strongly in cells expressing reduced levels of CypA ([@bib134], [@bib138]), again highlighting that small amounts of CypA may suffice to support efficient nidovirus replication (see above). Collectively, these observations indicate that CypA is an essential host factor that binds to arterivirus replication organelles and supports RNA synthesis ([Fig. 1](#f0005){ref-type="fig"}). The inhibition of EAV RNA synthesis by CsA treatment suggests that CypA has a direct role in this process, rather than being involved in the formation of replication organelles, which is in contrast to what has been reported for HCV ([@bib13], [@bib79]) (see below).

4. Cyps and their inhibitors in the replication of other RNA viruses {#s0080}
====================================================================

The importance of Cyps in RNA virus replication and the antiviral effects of Cyp inhibitors have been documented quite extensively. In this chapter, we will briefly summarize the most relevant findings regarding the involvement of Cyps in the replication of other groups of RNA viruses. In this respect, human immunodeficiency virus 1 (HIV-1), hepatitis C virus (HCV), and influenza virus have been studied in most detail, and these data have also been summarized previously in a number of excellent reviews ([@bib3], [@bib9], [@bib49], [@bib73]).

4.1. HIV-1 {#s0085}
----------

During HIV-1 infection, CypA plays a role in the disassembly stage of the HIV-1 capsid core and the nuclear import of the reverse-transcribed HIV-1 genome. However, the molecular details of this process remain poorly understood. CypA binds the capsid core by interacting with capsid protein (CA) monomers that enclose the viral genome. In general, it is believed that in this way CypA ensures that the HIV-1 genome, which following entry is reverse-transcribed into cDNA inside these capsid cores, reaches the nucleus before it is sensed by the immune system (reviewed in [@bib9]; [@bib49]). CsA and NIM-811 were shown to inhibit HIV-1 replication in human T cells by disrupting this CA-CypA interaction ([@bib4], [@bib29]). The hydrophobic pocket of CypA interacts with CA to catalyze the *cis/trans* isomerization of the Gly89--Pro90 peptide bond, which induces a conformational change in HIV-1 CA ([@bib6], [@bib30], [@bib33], [@bib122]). This event is thought to trigger the disassembly of the HIV-1 capsid core, although the available data is conflicting. Some researchers indeed showed that CypA binds CA to destabilize the capsid core ([@bib32]), while others found that CypA stabilizes the capsid core ([@bib112]). A third study suggests that this discrepancy may be caused by concentration differences, with low amounts of CypA stabilizing the core and high levels leading to its disassembly ([@bib68]).

The interaction with CA may also prevent CA from binding to a HIV-1 restriction factor, presumably TRIM5α, which was shown to restrict retrovirus replication in Old-World monkey cells ([@bib123], and reviewed in [@bib49]; [@bib75]). This hypothesis is strengthened by the observation that (New-World) owl monkey cells express a TRIM5-CypA fusion protein, in which the TRIM5α SPRY domain has been replaced with CypA. The CypA domain of this fusion protein directs the TRIM5α domain to the HIV-1 capsid core to restrict HIV-1 replication. Also, in contrast to the inhibition of HIV-1 infection by CsA in human T cells, treatment of owl monkey cells with this Cyp inhibitor enhanced HIV-1 replication. This increased replication efficiency is presumably mediated by a block of the TRIM5-CypA interaction with the HIV-1 CA ([@bib91], [@bib106]).

4.2. HCV {#s0090}
--------

After reports on the potent inhibition of HCV replication in hepatocytes by CsA ([@bib83], [@bib131]), CypA was identified as an essential host factor for HCV replication ([@bib12], [@bib56], [@bib84], [@bib140]). Its importance was further substantiated by the observation that HCV infection was restricted in CypA-knockout mice ([@bib20]). Subsequently, several key observations were made during studies aiming to elucidate the mechanism(s) by which CypA regulates HCV replication (for excellent reviews, see [@bib49]; [@bib66]):i.Inactivation of CypA\'s PPIase activity by mutagenesis revealed that this enzymatic activity is pivotal for efficient HCV replication in cell culture ([@bib12], [@bib74]);ii.CypA interacts directly with the HCV replication complex by binding to NS5A. Multiple proline residues located in NS5A domains II and III are determinants of CypA binding and are substrates for its PPIase activity ([@bib24], [@bib28], [@bib44], [@bib113]). Binding of CypA to NS5A domain II induces conformational changes in this domain that favor RNA binding and NS5A-NS5B interactions ([@bib28], [@bib89]);iii.Resistance to Cyp inhibitors requires mutations in NS5A ([@bib17], [@bib34], [@bib56]). The NS5A D320E mutation is assumed to contribute most to resistance and facilitates CypA-independent replication of HCV ([@bib17]);iv.There is growing evidence that the CypA-NS5A interaction is not directly linked to the RNA-synthesizing activity of the HCV replication complex, but merely is involved in the formation and stabilization of the HCV-induced membranous web (replication organelle) with which the replication complex is associated ([@bib13], [@bib79]).

The efficacy of CsA and its non-immunosuppressive analogs ALV, NIM811, and SCY-365 in blocking HCV infection in cell culture models ([@bib16], [@bib17], [@bib50], [@bib54], [@bib78], [@bib92], [@bib131]) ultimately led to the evaluation of these drugs in clinical trials, of which ALV reached the phase III clinical trial. Overall, these trials showed that ALV - when combined with direct-acting antivirals -- can contribute to an IFN-free pan-genotypic HCV therapy, although until date none of the Cyp inhibitors have been approved for HCV treatment. The outcome of these trials has been reviewed in detail in ([@bib48], [@bib81], [@bib86]).

4.3. Flaviviruses {#s0095}
-----------------

Besides HCV, CsA also inhibits the replication of other flaviviruses, as established for West Nile virus (WNV), dengue virus (DENV), and yellow fever virus (YFV) ([@bib99]). The latter study showed an essential role of CypA\'s PPIase activity in DENV and WNV replication. In the case of WNV and Japanese encephalitis virus (JEV), the inhibitory effect of CsA was attributed to blocking a functional CypA-NS5 interaction ([@bib99]), while CypA was shown to interact with NS4B during YFV infection ([@bib127]). Interestingly, JEV seems to depend mainly on enzymatically active CypB for its replication, mostly via an interaction with NS4A ([@bib55]).

4.4. Influenza viruses {#s0100}
----------------------

In contrast to CypA\'s proviral role in e.g. HIV-1 and HCV replication, CypA acts as a restriction factor for influenza virus replication (reviewed in [@bib73]). The multifunctional matrix (M1) protein is involved in various stages of the virus replication cycle. CypA interacts with the M1 protein to accelerate its degradation through the ubiquitin/proteasome-dependent pathway ([@bib70], [@bib72]). Overexpression of CypA in transgenic mice reduced influenza virus replication ([@bib61]). Furthermore, influenza A virus infection of macrophages isolated from these CypA-overexpressing mice showed an upregulation of host antiviral genes compared to macrophages from wild-type C57BL/6 mice. This upregulation may likely contribute to resistance of influenza virus infection in mice ([@bib61]).

Interestingly, the Cyp inhibitor CsA and other Cyp inhibitors exhibit broad-spectrum influenza virus A and B antiviral activity ([@bib41], [@bib77]). *In vivo* studies showed survival of CsA-treated mice that were infected with a lethal influenza virus dose ([@bib109]). Furthermore, Liu et al. claimed that CsA limits influenza A virus replication in a CypA-dependent and -independent manner: CsA increased CypA\'s binding affinity for M1 and at the same time decreased nuclear import of the influenza virus genome in CypA-depleted cells ([@bib71]).

5. Discussion and outlook {#s0105}
=========================

Efficient viral replication depends on the concerted interactions between viral proteins and host cell factors. Cyps were demonstrated to play a multifaceted role in the replication of a range of RNA viruses, which was investigated in most detail for HIV-1 and HCV. The key role of Cyps in the viral life cycle has been demonstrated by a wide variety of techniques, including the use of cells or mice partially or completely depleted for specific Cyps, by complementation studies with PPIase-deficient Cyp proteins or mutant viral proteins that are unable to interact with Cyps, using (non-)immunosuppressive Cyp inhibitors, and by the analysis of drug-resistant viruses.

For most viruses, CypA is believed to be the main Cyp involved in virus replication, but its specific mode of action in virus replication appears to differ greatly among viruses. For instance, CypA is believed to bind the HIV-1 CA to ensure that the reverse-transcribed HIV-1 genome reaches the nucleus before it is sensed by the immune system, while during HCV infection CypA is involved in the generation of virus-induced replication organelles and/or the proper folding of HCV proteins that interact with viral RNA or other viral proteins. Current data from others and our laboratory suggest a diverse role of Cyps, and especially CypA, in nidovirus replication. For example, CypA has been hypothesized to be incorporated into SARS-CoV virions ([@bib87]), which may suggest -- for reasons that are not fully understood at the moment -- that CypA\'s chaperone function enhances the infectivity of SARS-CoV. [@bib95] reported that a variety of Cyps, including CypA, is able to modulate NF-AT signaling in SARS-CoV-infected cells by interacting with SARS-CoV nsp1. However, the relevance of these results in the context of the viral replication cycle is currently unclear, as non-immunosuppressive analogs do not interfere with NF-AT signaling but do inhibit SARS-CoV replication.

In the case of the arterivirus EAV, CypA plays a role in viral RNA synthesis, albeit that its exact function is poorly understood. Whether CypA is also involved in the RNA synthesis activity of other nidoviruses warrants further investigation, e.g. by testing Cyp inhibitors on the activity of isolated replication complexes from nidovirus-infected cells. In any case, the mechanistic details of the interactions of nidoviral proteins and Cyps remain to be resolved, which may also provide a basis for new therapeutic approaches for other (nido)viruses that recruit Cyps as a host factor in their replication.

[^1]: DTM is an inhibitor of the parvulin Pin-1.

[^2]: Pin-1 is member of the parvulin family and not a cyclophilin protein family member.

[^3]: Only one inhibitor concentration used, no EC~50~ value was reported.

[^4]: Not reported.
